, 31 October 2025 NOTIFICATION LETTER 通知信函 The following document(s) of Wai Chun Bio-Technology Limited (the "Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.0660.hk and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites"):- Dear Non-registered Shareholder(s)(Note 1) (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 660) • Annual Report 2024/2025 You may at any time ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 660) NOTIFICATION LETTER 通知信函 You may at any time send your request in writing to the Company (c/o its Hong Kong Branch Share Registrar at the above address or by email to the above email address) to request for printed copies of the Corporate Communications. If you have received notification of the publication of the Corporate Communications on the Websites and for any reason have difficulty in gaining access to ...

（於開曼群島註冊成立之有限 公 司） （股份代 號 ： 0 6 6 0） 2024/2025 年 報 Annual Report 2021-2021 Annual Report 年 報 20 2 4 / 2 5 2024/2025 ANNUAL REPORT 目 錄 2 公司資料 3 管理層討論及分析 7 董事履歷詳情 8 董事會報告 19 企業管治報告 30 環境、社會及管治報告 60 獨立核數師報告 67 綜合損益表 68 綜合損益及其他全面收益表 69 綜合財務狀況表 71 綜合權益變動表 72 綜合現金流量表 74 綜合財務報表附註 140 五年財務概要 公司資料 董事會 執行董事 林家俊 （主席） 獨立非執行董事 黃保強 （於二零二五年五月十二日獲委任） 王子牛 （於二零二五年六月五日獲委任） 許慧齡 （於二零二五年六月五日獲委任） 萬 波 （於二零二五年六月五日辭任） 何 濤 （於二零二五年六月五日辭任） 龔映彤 （於二零二四年九月四日獲委任及 於二零二五年二月十四日辭任） 授權代表 林家俊 范德偉 （於二零二四年六月一日獲委任及 於二零二四年十月十七日辭任） 錢盈盈 （於二零二四年十月十八日獲委 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited 茲 提 述 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 三 月 二 十 八 日 之 通 函（「通函一」），本 公 司 日 期 為 二 零 二 五 年 四 月 二 十 三 日、二 零 二 五 年 五 月 二 十 一 日、二 零 二 五 年 八 月 二 十 一 日、二 零 二 五 年 九 月 十 一 日 及 二 零 二 五 年 九 月 二 十 九 日 的 公 告（「該等公告」）。除 另 有 界 定 或 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 通 函一及該等公告所界定者具有相同涵義。 – 1 – 誠 如 該 通 函 與 該 等 公 告 所 披 露，股 本 重 組 的 生 效 日 期 及 時 間 預 計 為 二 零 二 五 年 十 月 二 十 八 日，新 普 通 股 ...

Core Viewpoint - Fuyao's revenue in 3Q25 increased by 18.9% YoY, with mixed regional performance; domestic automotive glass sales slightly missed expectations while overseas revenue showed strong growth momentum [1][2] Financial Performance - 3Q25 revenue reached RMB 11.85 billion, with a 2.7% sequential increase from 2Q; domestic automotive glass sales rose by 16.2% YoY to RMB 5.8 billion, slightly below estimates due to lower-than-expected domestic PV output growth [2] - Overseas automotive glass revenue grew approximately 29% YoY, driven by robust export demand and new capacity ramp-up in the US [2] - Attributable net income increased by 14.1% YoY to RMB 2.3 billion, modestly below estimates due to higher foreign exchange losses and tax expenses [1] Margin Analysis - Gross margin in 3Q25 slightly declined by 0.6 percentage points QoQ to 37.9%, primarily due to higher domestic OEM rebates and reduced profitability in the US [3] - The improved product structure led to an 8% YoY increase in automotive glass average selling price (ASP) in 3Q25 [2] Overseas Operations - SAM's revenue in 3Q25 fell 53% YoY to EUR 24.6 million, largely due to a high base from customer recoveries in 3Q24; excluding this impact, revenue declined by 19% YoY [4] - US base revenue grew by 4% QoQ to US$303 million, marking three consecutive quarters of growth [4] Leadership Transition - Founder Cho Tak Wong's early resignation as Chairman is viewed as a planned family transition, with his son CAO Hui assuming the role immediately; this shift is part of the company's strategy to optimize governance and mitigate keyman risks [6][8] - Post-resignation, Cho Tak Wong will remain as a lifetime honorary chairman and board member, transitioning to a strategic advisory role [6] Valuation - The company maintains its 2025-26 net income forecasts at RMB 9.32 billion and RMB 10 billion, respectively; despite potential near-term share price fluctuations due to leadership changes, the long-term core story remains intact [7][8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑋俊生物科技有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00660 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 400,000,000 | HKD | | 0.25 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 400,000,000 | HKD | | 0.25 | HKD | | 100,000,000 | | 2. 股份 ...

Stock Option Plan - The stock option plan allows the company to grant rights to subscribe for up to 15,954,685 shares, representing approximately 9.30% of the issued shares as of the date of the 2024 annual report[3]. - As of June 30, 2024, a total of 8,958,290 stock options have lapsed, with no options granted, exercised, or cancelled during the fiscal year ending June 30, 2024[3]. - The number of stock options available for grant under the plan as of July 1, 2023, and June 30, 2024, is 6,996,395 and 15,954,685, respectively[3]. - The stock option plan is effective for a period of 10 years from the adoption date, unless otherwise cancelled or amended[3]. - No stock options were granted to connected persons or service providers that exceeded 0.1% of the relevant class of issued shares during any 12-month period as of July 1, 2023, and June 30, 2024[5]. - Any stock options granted must be approved by shareholders at a general meeting[4]. - The total value of stock options granted to connected persons must not exceed HKD 5,000,000 based on the closing price of shares on the grant date[4]. - The company emphasizes the importance of shareholder approval for any stock option grants to ensure compliance with listing rules[4]. Governance and Oversight - The company’s board of directors includes executive and independent non-executive directors, ensuring governance and oversight[7]. - The information in this announcement does not affect other data contained in the 2024 annual report[6].

Core Viewpoint - Wei Jun Biotechnology (00660.HK) reported a revenue of approximately HKD 377 million for the fiscal year ending June 30, 2025, representing an increase of about 1.9% compared to the previous year. The company also improved its net loss to approximately HKD 14.6 million from HKD 44.2 million in the prior year, primarily due to a significant reduction in impairment losses on non-financial assets [1]. Financial Performance - The group's revenue and gross profit remained relatively stable compared to the previous year, with a reported revenue of approximately HKD 377 million [1]. - The net loss for the fiscal year ending June 30, 2025, was approximately HKD 14.6 million, a significant improvement from the net loss of approximately HKD 44.2 million for the fiscal year ending June 30, 2024 [1]. - The improvement in net loss was mainly attributed to a substantial decrease in impairment losses on non-financial assets during the reporting period [1]. Strategic Outlook - The company plans to continue pursuing strategic acquisitions to capture new business opportunities in the Chinese market, aiming to further strengthen its revenue and profit base [1]. - The company is actively seeking projects with growth potential for acquisition or investment and is in discussions with various parties regarding such opportunities [1].

Financial Performance - The total revenue for the year ended June 30, 2025, was HKD 377,168,000, representing a 1% increase from HKD 370,069,000 in the previous year[2] - Gross profit for the same period was HKD 36,004,000, up from HKD 34,181,000, indicating a growth of 5%[2] - The net loss for the year was HKD 10,701,000, a significant improvement compared to a net loss of HKD 65,707,000 in the prior year, reflecting a reduction of approximately 84%[2] - The company's basic and diluted loss per share improved to HKD (8.43) from HKD (25.78) year-over-year[2] - The group reported a net loss of approximately HKD 14,623,000 for the year ending June 30, 2025, compared to a net loss of approximately HKD 44,212,000 for the previous year, indicating an improvement in financial performance[32] - The company reported a loss attributable to owners of approximately HKD 14.6 million for the year ending June 30, 2025, an improvement from a loss of HKD 44.2 million in the previous year[48] Assets and Liabilities - Total assets as of June 30, 2025, amounted to HKD 214,655,000, compared to HKD 209,498,000 in the previous year, showing a slight increase[4] - Current liabilities increased to HKD 277,308,000 from HKD 253,847,000, indicating a rise of approximately 9%[5] - The total accounts receivable amounted to HKD 31,908,000 as of June 30, 2025, down from HKD 34,945,000 in the previous year, with a net accounts receivable of HKD 28,787,000 after deducting provisions for losses[34] - As of June 30, 2025, the group's total liabilities were approximately HKD 178.0 million, an increase from HKD 135.9 million the previous year[51] - The net current liabilities were approximately HKD 170.5 million, compared to HKD 139.4 million as of June 30, 2024[51] - The company’s net debt to total assets ratio was approximately 79.9%, up from 63.8% the previous year[51] Cash Flow and Financial Stability - The company's cash and cash equivalents rose to HKD 6,558,000 from HKD 2,161,000, marking a significant increase of 204%[4] - The group recognized a foreign exchange gain of HKD 1,000 from overseas operations, contrasting with a loss of HKD 72 in the previous year[3] - The board believes that the group will have sufficient cash resources to meet its operational and financing needs within the next twelve months from the announcement date, thus justifying the preparation of financial statements on a going concern basis[10] - The group had a total of approximately HKD 20.3 million in assets pledged as collateral for bank borrowings as of June 30, 2025[54] - The company has implemented measures to ensure financial stability, including obtaining loans from the ultimate holding company and closely monitoring administrative expenses[56] Operational Highlights - The group plans to pursue strategic acquisitions to capture new business opportunities in the mainland China market and strengthen its revenue and profitability fundamentals[12] - The group is actively negotiating with potential investors to raise sufficient funds through financing arrangements[11] - The group has reduced its workforce to 61 employees as of June 30, 2025, down from 140 employees the previous year[57] - No significant acquisitions or disposals of subsidiaries occurred during the year ending June 30, 2025[58] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the year ending June 30, 2025[59] Expenses and Costs - Sales expenses increased by approximately 13.3%, rising from HKD 12.4 million to HKD 14.1 million[45] - Administrative expenses slightly increased by about 2.6%, from HKD 20.3 million to HKD 20.8 million[46] - The group’s research and development expenses were HKD 1,610,000 for the year ending June 30, 2025, compared to HKD 2,719,000 in the previous year, indicating a reduction in R&D investment[31] - The group recognized an impairment loss of approximately HKD 1.7 million for non-current assets, significantly reduced from HKD 58.1 million in the previous year[47] Governance and Reporting - The board has resolved not to recommend the payment of a final dividend for the year ending June 30, 2025[55] - The company has adopted the corporate governance code as per the listing rules, with some deviations noted[61] - The audit committee has reviewed the annual results for the year ending June 30, 2025, in conjunction with the external auditor[66] - The company will publish its annual report containing all information required by listing rules at an appropriate time[68] - The board expresses gratitude to all employees and management for their contributions during the year[69] - The board members include executive director Lin Jia Jun (Chairman and CEO) and independent non-executive directors Huang Bao Qiang, Wang Zi Niu, and Xu Hui Ling[70]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited （於開曼群島註冊成立之有限公司） （股份代號：660） (i)有關建議股本重組以及 建議更改現有可換股債券條款之關連交易經修訂預期時間表； 及 (ii)延長認購協議之最後截止日期 股本重組之更新資料及經修訂預期時間表 茲 提 述 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 三 月 二 十 八 日 之 通 函（「通函一」），以 及 本 公 司 日 期 為 二 零 二 五 年 四 月 二 十 三 日、二 零 二 五 年 五 月 二 十一日、二零二五年八月二十一日及二零二五年九月十一日的公告（「該等公告」）。 除 另 有 界 定 或 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 通 函 一 及 該 等 公 告 所 界 定 者 具有相同涵義。 誠 如 該 通 函 與 該 等 ...